729-46-4
729-46-4 结构式
基本信息
Bis(morpholinothiocarbonyl) disulfide
Bis(morpholinocarbonothioyl) persulfide
4,4'-(dithiodicarbonothioyl)dimorpholine
Morpholine, 4,4-(dithiodicarbonothioyl)bis-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/09/19 | S0983 | 4,4'-(dithiodicarbonothioyl)dimorpholine JX06 | 729-46-4 | 5mg | 958.23元 |
| 2025/09/19 | S0983 | 4,4'-(dithiodicarbonothioyl)dimorpholine JX06 | 729-46-4 | 25mg | 2858.31元 |
| 2025/05/22 | HY-19564 | 4,4'-(dithiodicarbonothioyl)dimorpholine JX06 | 729-46-4 | 5mg | 500元 |
常见问题列表
| Target | Value |
|
PDK1
(Cell-free assay) | 0.049 μM |
|
PDK2
(Cell-free assay) | 0.101 μM |
|
PDK3
(Cell-free assay) | 0.313 μM |
JX06 barely shows inhibitory activity against PDK4 at a concentration of 10 μM.
JX06 (1-10 μM; 48 hours) induces cell apoptosis in cancer cells with high ECAR/OCR.
JX06 (0-0.6 μM; 72 hours) dose-dependently suppresses the growth of A549 cells.
JX06 (0.1-10 μM; 6-24 hours) inhibits PDHA1 phosphorylation in A549 cells in a time- and dose-dependent manner.
JX06 (1-10 μM) increases glucose uptake and intracellular ATP level and reduces aerobic glycolysis determined by the lactate production in A549 cells.
JX06 (1-10 μM; 24 hours) induces ROS generation in cancer cells with high extracellular acidification rate (ECAR)/ oxygen consumption rate (OCR) .
Apoptosis Analysis
| Cell Line: | A549, EBC-1, HT-29 and H460 cells |
| Concentration: | 0, 1, 3, 10 μM |
| Incubation Time: | 48 hours |
| Result: | Induces cell apoptosis in A549 and EBC-1 cells. |
Cell Viability Assay
| Cell Line: | A549 cells |
| Concentration: | 0, 0.2, 0.4, 0.6 μM |
| Incubation Time: | 72 hours |
| Result: | Inhibits the viability of A549 cells in a dose dependent manner. |
Western Blot Analysis
| Cell Line: | A549 cells |
| Concentration: | 0, 0.1, 0.3, 1, 3, 10 μM |
| Incubation Time: | 0, 6, 12, 24 hours |
| Result: | Decreased PDHA1 phosphorylation at both serine 293 and serine 232 (S293 and S232) in a time- and dose-dependent manner. |
JX06 (40-80 mg/kg; i.p. for 21 days) inhibits tumor growth in vivo.
| Animal Model: | A549 subcutaneous xenograft mice |
| Dosage: | 40, 80 mg/kg |
| Administration: | I.p. injections for 21 days |
| Result: |
Reduced tumor weights and 67.5% tumor volume at the dose of 80 mg/kg compared with the vehicle control.
Well tolerated at the administration dose. |